Literature DB >> 23197496

Guardian and selective killer: the versatile functions of TLR3 in hepatocellular carcinoma.

Chen Liu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23197496      PMCID： PMC3514168          DOI： 10.1093/jnci/djs475

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  17 in total

1.  Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF.

Authors:  Kui Li; Eileen Foy; Josephine C Ferreon; Mitsuyasu Nakamura; Allan C M Ferreon; Masanori Ikeda; Stuart C Ray; Michael Gale; Stanley M Lemon
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-14       Impact factor: 11.205

2.  Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration.

Authors:  Y Wada; O Nakashima; R Kutami; O Yamamoto; M Kojiro
Journal:  Hepatology       Date:  1998-02       Impact factor: 17.425

Review 3.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.

Authors:  Hashem B El-Serag; K Lenhard Rudolph
Journal:  Gastroenterology       Date:  2007-06       Impact factor: 22.682

4.  Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system.

Authors:  Haizhen Zhu; Huijia Dong; Erika Eksioglu; Alan Hemming; Mengde Cao; James M Crawford; David R Nelson; Chen Liu
Journal:  Gastroenterology       Date:  2007-09-16       Impact factor: 22.682

Review 5.  Evasion of intracellular host defence by hepatitis C virus.

Authors:  Michael Gale; Eileen M Foy
Journal:  Nature       Date:  2005-08-18       Impact factor: 49.962

6.  A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.

Authors:  Bastian Hoechst; Lars A Ormandy; Matthias Ballmaier; Frank Lehner; Christine Krüger; Michael P Manns; Tim F Greten; Firouzeh Korangy
Journal:  Gastroenterology       Date:  2008-03-21       Impact factor: 22.682

7.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

8.  Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor.

Authors:  Bastian Hoechst; Torsten Voigtlaender; Lars Ormandy; Jaba Gamrekelashvili; Fei Zhao; Heiner Wedemeyer; Frank Lehner; Michael P Manns; Tim F Greten; Firouzeh Korangy
Journal:  Hepatology       Date:  2009-09       Impact factor: 17.425

Review 9.  Toll-like receptors expressed in tumor cells: targets for therapy.

Authors:  Li Yu; Shangwu Chen
Journal:  Cancer Immunol Immunother       Date:  2008-02-07       Impact factor: 6.968

10.  Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients.

Authors:  Valerie Chew; Charlene Tow; Caleb Huang; Emilie Bard-Chapeau; Neal G Copeland; Nancy A Jenkins; Achim Weber; Kiat Hon Lim; Han Chong Toh; Mathias Heikenwalder; Irene Oi-Lin Ng; Alessandra Nardin; Jean-Pierre Abastado
Journal:  J Natl Cancer Inst       Date:  2012-11-29       Impact factor: 13.506
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.